At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 30 target
Drug / intervention
Bortezomib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Efficacy and Safety of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB Diffuse Large B-cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Bortezomib, Gemcitabine, and 2 other interventions for Diffuse Large B-cell Lymphoma. Targeting 30 participants across 1 site.
Detailed Summary
This study is to evaluate the efficacy and safety of Bortezomib plus GDP in the treatment of non-GCB DLBCL patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-cell Lymphoma
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
First PostedSep 2015
Primary CompletionMay 2018
TodayJul 2026
First PostedSep 4, 2015
Enrollment StartMay 1, 2015
Primary CompletionMay 1, 2018
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 10.8 years ago
Interventions
Bortezomibdrug
Bortezomib IV
Gemcitabinedrug
Gemcitabine IV
Dexamethasonedrug
Dexamethasone IV
Cisplatindrug
Cisplatin IV